Molecular Pharmacology Training Program

分子药理学培训项目

基本信息

  • 批准号:
    10398169
  • 负责人:
  • 金额:
    $ 41.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Pharmacology is at a crossroads. Although technological advances in chemistry and biology have transformed drug discovery, our ability to develop new therapeutics has lagged behind our clinical needs. This gap reflects a disconnect between basic science discovery and translational research, and addressing this challenge will require scientists who can bridge these two areas. Toward this goal, the Stanford Molecular Pharmacology Training Program (MPTP) aims to empower predoctoral students across the biosciences with specialized training in drug discovery and development. The MPTP is founded on the rich history of pharmacology research and education at Stanford, and it now transcends conventional academic boundaries. Our training program draws upon an outstanding group of 26 highly collaborative Stanford faculty from multiple departments, and it builds upon the strength of SPARK, a translational research initiative that was created at Stanford in 2006. In addition to their independent research with MPTP faculty, our trainees receive formal course work in drug discovery, and they attend weekly presentations by SPARK-affiliated experts in pharma/biotech, patent law, venture capital, clinical medicine, and other areas related to therapeutic development. MPTP students also participate in summer biotech internships and clinical shadowing opportunities, supplementing their academic training with industrial and clinical experiences. These training activities are integrated with courses on the responsible conduct of research, rigor, and reproducibility, weekly student/faculty research forums, annual retreats, grant writing and science communication workshops, and outreach opportunities. Our predoctoral students are also encouraged to propose translational projects, which are reviewed and funded by SPARK on a competitive basis. These team-based projects provide hands- on, real-world experience in therapeutic development and direct interactions with industry veterans and experts. Our program carefully tracks student research progress, faculty mentorship, and program effectiveness to enable the MPTP to continually evolve to meet its educational mission. To train scientific leaders and innovators who will impact communities throughout the United States, we have also established recruitment and retention strategies to foster student diversity, leveraging Stanford resources and mobilizing the MPTP community. Through its innovative curriculum and partnerships with SPARK and industry, the MPTP will impart its students with rigorous training in basic science and an understanding of drug discovery and development. Graduates of our training program will be uniquely able to translate fundamental discoveries into clinical advances, and they will be well- positioned to become scientific leaders in academia, industry, government, and other sectors.
药理学正处于十字路口。尽管化学和生物方面的技术进步已经改变了 在药物发现方面,我们开发新疗法的能力已经落后于我们的临床需求。这一差距反映了 基础科学发现和转化研究之间的脱节,解决这一挑战将需要 能够在这两个领域架起桥梁的科学家。为了实现这一目标,斯坦福大学分子药理学培训项目 (MPTP)旨在通过药物发现和药物开发方面的专门培训,增强生物科学领域的博士前学生能力 发展。 MPTP是建立在斯坦福大学丰富的药理学研究和教育历史上的,现在它 超越了传统的学术界限。我们的培训计划吸引了26人的优秀团队 来自多个部门的协作斯坦福教师,它建立在Spark的优势之上,Spark是一种翻译 斯坦福大学于2006年创建的研究计划。除了他们与MPTP教职员工的独立研究外, 我们的实习生接受药物发现方面的正式课程工作,他们每周都会参加Spark附属公司的报告。 制药/生物技术、专利法、风险投资、临床医学和其他与治疗相关的领域的专家 发展。MPTP学生还参加暑期生物技术实习和临床跟踪机会, 用工业和临床经验补充他们的学术培训。 这些培训活动与负责任的研究、严谨和 可重现性,每周学生/教师研究论坛,年度务虚会,拨款撰写和科学交流 讲习班和外展机会。我们的博士前学生也被鼓励提出翻译建议 项目,由Spark在竞争的基础上进行审查和资助。这些基于团队的项目提供了手- 在治疗开发方面的实际经验以及与行业资深人士和专家的直接互动。我们的 该计划仔细跟踪学生的研究进展、教师指导和计划有效性,以使 MPTP将不断发展,以满足其教育使命。培养将产生影响的科学领导者和创新者 在美国各地的社区,我们还制定了招聘和留住战略,以促进 学生多样性,利用斯坦福大学的资源,动员MPTP社区。 通过其创新的课程以及与Spark和行业的合作伙伴关系,MPTP将教授其学生 受过严格的基础科学培训,对药物发现和开发有一定的了解。我们的毕业生 培训计划将独一无二地能够将基础发现转化为临床进步,而且它们将很好地- 定位成为学术界、工业界、政府和其他领域的科学领袖。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES K CHEN其他文献

JAMES K CHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES K CHEN', 18)}}的其他基金

Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
  • 批准号:
    10640894
  • 财政年份:
    2021
  • 资助金额:
    $ 41.63万
  • 项目类别:
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
  • 批准号:
    10407067
  • 财政年份:
    2021
  • 资助金额:
    $ 41.63万
  • 项目类别:
Targeting colorectal cancer stem cells with ALDH1B1 antagonists
使用 ALDH1B1 拮抗剂靶向结直肠癌干细胞
  • 批准号:
    10299142
  • 财政年份:
    2021
  • 资助金额:
    $ 41.63万
  • 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
  • 批准号:
    10470960
  • 财政年份:
    2019
  • 资助金额:
    $ 41.63万
  • 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
  • 批准号:
    10018041
  • 财政年份:
    2019
  • 资助金额:
    $ 41.63万
  • 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
  • 批准号:
    10456372
  • 财政年份:
    2019
  • 资助金额:
    $ 41.63万
  • 项目类别:
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives
开发变构 HIPK4 抑制剂作为非激素男性避孕药
  • 批准号:
    10673682
  • 财政年份:
    2019
  • 资助金额:
    $ 41.63万
  • 项目类别:
Chemical tools for developmental biology
发育生物学化学工具
  • 批准号:
    10369652
  • 财政年份:
    2018
  • 资助金额:
    $ 41.63万
  • 项目类别:
Chemical tools for developmental biology
发育生物学化学工具
  • 批准号:
    10623101
  • 财政年份:
    2018
  • 资助金额:
    $ 41.63万
  • 项目类别:
Gli1-selective inhibitors of the Hedgehog signaling pathway
Hedgehog 信号通路的 Gli1 选择性抑制剂
  • 批准号:
    9100825
  • 财政年份:
    2015
  • 资助金额:
    $ 41.63万
  • 项目类别:

相似海外基金

National Career Development Program for Researchers in Pediatric Clinical Pharmacology
儿科临床药理学研究人员国家职业发展计划
  • 批准号:
    11001312
  • 财政年份:
    2024
  • 资助金额:
    $ 41.63万
  • 项目类别:
Training in Systems Pharmacology and Toxicology (T-SPaT)
系统药理学和毒理学培训 (T-SPaT)
  • 批准号:
    10714918
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
Impact of metabotropic glutamate receptor heteromerization on signaling and pharmacology
代谢型谷氨酸受体异聚化对信号传导和药理学的影响
  • 批准号:
    10637938
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
Clinical Pharmacology Quality Assurance (CPQA)
临床药理学质量保证(CPQA)
  • 批准号:
    10850504
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
PHARMACOLOGY CONSULTING SERVICES
药理学咨询服务
  • 批准号:
    10924442
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013
基本标题:预防临床前药理学和毒理学任务订单标题:使用人单克隆抗体 ATI-1013 进行尼古丁减少治疗
  • 批准号:
    10932479
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
Pharmacology Consulting Services in relation to Pharmaceutical Development with Pain expertise. 09/12/2023 - 09/11/2024
与具有疼痛专业知识的药物开发相关的药理学咨询服务。
  • 批准号:
    10949065
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
    Fellowship Programs
Understanding the clinical pharmacology of marijuana-tobacco co-administration
了解大麻-烟草联合用药的临床药理学
  • 批准号:
    10660409
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
Learning How to Give Casual Explanations for Large Scale Virtual and Morphological Pharmacology
学习如何对大规模虚拟和形态药理学进行随意解释
  • 批准号:
    10713386
  • 财政年份:
    2023
  • 资助金额:
    $ 41.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了